Department of Urology, Stanford University School of Medicine, Stanford, California.
Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
Cancer. 2021 Apr 1;127(7):1102-1113. doi: 10.1002/cncr.33341. Epub 2020 Nov 25.
Estimates of overall patient health are essential to inform treatment decisions for patients diagnosed with cancer. The authors applied XWAS methods, herein referred to as "laboratory-wide association study (LWAS)", to evaluate associations between routinely collected laboratory tests and survival in veterans with prostate cancer.
The authors identified 133,878 patients who were diagnosed with prostate cancer between 2000 and 2013 in the Veterans Health Administration using any laboratory tests collected within 6 months of diagnosis (3,345,083 results). Using the LWAS framework, the false-discovery rate was used to test the association between multiple laboratory tests and survival, and these results were validated using training, testing, and validation cohorts.
A total of 31 laboratory tests associated with survival met stringent LWAS criteria. LWAS confirmed markers of prostate cancer biology (prostate-specific antigen: hazard ratio [HR], 1.07 [95% confidence interval (95% CI), 1.06-1.08]; and alkaline phosphatase: HR, 1.22 [95% CI, 1.20-1.24]) as well laboratory tests of general health (eg, serum albumin: HR, 0.78 [95% CI, 0.76-0.80]; and creatinine: HR, 1.05 [95% CI, 1.03-1.07]) and inflammation (leukocyte count: HR, 1.23 [95% CI, 1.98-1.26]; and erythrocyte sedimentation rate: HR, 1.33 [95% CI, 1.09-1.61]). In addition, the authors derived and validated separate models for patients with localized and advanced disease, identifying 28 laboratory markers and 15 laboratory markers, respectively, in each cohort.
The authors identified routinely collected laboratory data associated with survival for patients with prostate cancer using LWAS methodologies, including markers of prostate cancer biology, overall health, and inflammation. Broadening consideration of determinants of survival beyond those related to cancer itself could help to inform the design of clinical trials and aid in shared decision making.
This article examined routine laboratory tests associated with survival among veterans with prostate cancer. Using laboratory-wide association studies, the authors identified 31 laboratory tests associated with survival that can be used to inform the design of clinical trials and aid patients in shared decision making.
评估患者整体健康状况对于为癌症患者的治疗决策提供信息至关重要。作者应用了 XWAS 方法(本文称为“实验室广泛关联研究(LWAS)”),以评估常规收集的实验室检测与退伍军人前列腺癌患者生存之间的关联。
作者使用在诊断后 6 个月内采集的任何实验室检测(334.5083 次结果),在退伍军人健康管理局(VA)中确定了 2000 年至 2013 年间被诊断为前列腺癌的 133878 名患者。作者使用 LWAS 框架,采用错误发现率来检验多个实验室检测与生存之间的关联,并且使用训练、测试和验证队列对这些结果进行了验证。
共有 31 项与生存相关的实验室检测符合严格的 LWAS 标准。LWAS 证实了前列腺癌生物学标志物(前列腺特异性抗原:风险比[HR],1.07[95%置信区间(95%CI),1.06-1.08];碱性磷酸酶:HR,1.22[95%CI,1.20-1.24])以及一般健康状况的实验室检测(例如,血清白蛋白:HR,0.78[95%CI,0.76-0.80];和肌酐:HR,1.05[95%CI,1.03-1.07])和炎症(白细胞计数:HR,1.23[95%CI,1.98-1.26];红细胞沉降率:HR,1.33[95%CI,1.09-1.61])的标志物。此外,作者为局限性疾病和晚期疾病患者分别推导和验证了单独的模型,在每个队列中分别确定了 28 个和 15 个实验室标志物。
作者使用 LWAS 方法,包括前列腺癌生物学标志物、整体健康和炎症标志物,确定了与前列腺癌患者生存相关的常规收集的实验室数据。除了与癌症本身相关的生存决定因素之外,更广泛地考虑生存决定因素可以帮助为临床试验设计提供信息,并帮助患者进行共同决策。
本文研究了退伍军人前列腺癌患者的生存与常规实验室检查之间的关系。作者使用实验室广泛关联研究(LWAS)方法,确定了 31 个与生存相关的实验室检测,可用于为临床试验设计提供信息,并帮助患者共同决策。